On Aug 29, we issued an updated research report on Radnor, PA-based VWR Corporation which offers laboratory products, services and solutions. The company currently carries a Zacks Rank #2 (Buy).
We are eagerly waiting for the closing of VWR’s $6.4 billion acquisition by Avantor, a global supplier of ultra-high-purity materials for life sciences and advanced technology industries.
Post-closing (expected in the fourth quarter of 2017), the consolidated entity should create a major consumables-focused solutions and services provider to high-growth life sciences and advanced technologies industries. The buyout will build on Avantor’s strengths, including its cGMP (current good manufacturing practice) processes, a significant exposure to the emerging markets and VWR’s vital position across both Americas as well as Europe.
The combined company will therefore be serving a global customer base in all areas of activities from research through production, thus reflecting a unique advantage in a fast-growing marketplace.
From shareholders’ point of view, this potential merger with Avantor seems a beneficial move at the moment. The consolidation deal has been fixed at $33.25 per share in cash of VWR common stock, representing an enterprise value of approximately $6.4 billion. The purchase price represents an approximate 17% premium to the unaffected closing stock price as of May 2, 2017, the day before market speculations over a potential sale of VWR started.
Notably, the stock price has already inched closer to Avantor’s offer price while investors wait for the merger’s closure. Hence, the short-term upside potential of VWR is limited now.
Other Key Picks
A few other top-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2. You cansee the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.04% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has surged 26.1% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 2.3% over the last six months.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
On Aug 29, we issued an updated research report on Radnor, PA-based VWR Corporation which offers laboratory products, services and solutions. The company currently carries a Zacks Rank #2 (Buy).
We are eagerly waiting for the closing of VWR’s $6.4 billion acquisition by Avantor, a global supplier of ultra-high-purity materials for life sciences and advanced technology industries.
Post-closing (expected in the fourth quarter of 2017), the consolidated entity should create a major consumables-focused solutions and services provider to high-growth life sciences and advanced technologies industries. The buyout will build on Avantor’s strengths, including its cGMP (current good manufacturing practice) processes, a significant exposure to the emerging markets and VWR’s vital position across both Americas as well as Europe.
The combined company will therefore be serving a global customer base in all areas of activities from research through production, thus reflecting a unique advantage in a fast-growing marketplace.
From shareholders’ point of view, this potential merger with Avantor seems a beneficial move at the moment. The consolidation deal has been fixed at $33.25 per share in cash of VWR common stock, representing an enterprise value of approximately $6.4 billion. The purchase price represents an approximate 17% premium to the unaffected closing stock price as of May 2, 2017, the day before market speculations over a potential sale of VWR started.
Notably, the stock price has already inched closer to Avantor’s offer price while investors wait for the merger’s closure. Hence, the short-term upside potential of VWR is limited now.
Other Key Picks
A few other top-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2. You cansee the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.04% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has surged 26.1% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 2.3% over the last six months.
One Simple Trading Idea
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars.
This proven stock-picking system is grounded on a single big idea that can be fortune shaping and life changing. You can apply it to your portfolio starting today.
Learn more >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on EW - FREE
Get the latest research report on IDXX - FREE
Get the latest research report on LNTH - FREE